A first-in-man phase 1 study of CUDC-907, a first-in-class chemically-designed dual inhibitor of PI3K and HDAC in patients with refractory or relapsed lymphoma and multiple myeloma Meeting Abstract
| Authors: | Younes, A.; Flinn, I. W.; Oki, Y.; Copland, A.; Fattaey, A.; Lai, C. J.; Laliberte, R.; Voi, M.; Berdeja, J. G. |
| Abstract Title: | A first-in-man phase 1 study of CUDC-907, a first-in-class chemically-designed dual inhibitor of PI3K and HDAC in patients with refractory or relapsed lymphoma and multiple myeloma |
| Meeting Title: | 55th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 122 |
| Issue: | 21 |
| Meeting Dates: | 2013 Dec 7-10 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2013-11-15 |
| Language: | English |
| ACCESSION: | WOS:000435860200023 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V122.21.4363.4363 |
| Notes: | Meeting Abstract: 4363 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work